结晶工艺开发

晶云药物是一家技术驱动的，专注于药物晶型研究、制剂开发和生产以及临床供应的CRO/CDMO，致力于为小分子新药客户提供量身定制的“首次正确”的晶型和制剂。 晶云药物成立于2010年，在中国苏州、美国新泽西和加拿大多伦多均设有研发和生产中心，拥有一支超过250人的专业团队，已与全球1000多家制药企业展开合作，为2000多个新药化合物提供专业技术方案。在中国排名前20的创新药企业中，有19家选择了晶云药物的服务；在全球排名前10的制药企业中，有8家是晶云药物的客户。Crystal Pharmatech, established in 2010, is a global company with approximately 250 employees and three R&D centers located in Suzhou (China), New Jersey (USA), and Toronto (Canada). Our key differentiator is our integrated and specialized services, including API solid-state research, crystallization, preformulation, formulation development, and manufacturing. With an average of 20 years of experience, our scientific leadership team has successfully delivered over 100 early phase and 19 commercialized products for global pharmaceutical companies. We have served over 1,000 clients, supporting more than 2,000 new chemical entities.